ORIGO BIOPHARMA
Origo Biopharma is a biotech company, specializes in research and development of immunotherapeutic products that address health disorders related to TGF-β signaling dysfunction, among this cancer and fibrosis.
ORIGO BIOPHARMA
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
San Ciprián De Viñas, Galicia, Spain
Country:
Spain
Website Url:
http://www.origobiopharma.com
Total Employee:
1+
Status:
Active
Total Funding:
2.3 M EUR
Technology used in webpage:
SPF Euro Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Person Schema Google Google Cloud Gravatar Profiles Sophos
Current Advisors List
Board_member
2020-07-07
Current Employees Featured
Ramon Bosser CEO @ Origo Biopharma
CEO
2019-07-01
Carme Pampín Casal Co-founder @ Origo Biopharma
Co-founder
2019-01-01
Founder
Investors List
Xesgalicia
Xesgalicia investment in Seed Round - Origo Biopharma
Asabys Partners
Asabys Partners investment in Seed Round - Origo Biopharma
Official Site Inspections
http://www.origobiopharma.com
- Host name: 7.228.214.35.bc.googleusercontent.com
- IP address: 35.214.228.7
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Origo Biopharma"
Origo Biopharma | Paving the way for new drugs
We would like to show you a description here but the site won’t allow us.See details»
Origo Biopharma - Asabys Partners
The combined organization will focus on translating growth factor signaling pathways into innovative therapies. Agomab’s hepatocyte growth factor (HGF)-targeting monoclonal antibodies together with Origo’s small molecule …See details»
Origo Biopharma - Crunchbase Company Profile
Origo Biopharma is a biotech company. Origo Biopharma is a biotech company, specializes in research and development of immunotherapeutic products that address health disorders related to TGF-β signaling dysfunction, among this …See details»
Agomab Therapeutics to Acquire Origo Biopharma
The combined organization will focus on translating growth factor signaling pathways into innovative therapies. Agomabs hepatocyte growth factor (HGF)-targeting monoclonal …See details»
Origo Biopharma - Products, Competitors, Financials, Employees ...
Origo Biopharma designs and develops new organ-restricted chemical entities that addresses unmet medical needs in cancer and fibrosis. On October 28th, 2021, Origo Biopharma was …See details»
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28 th, 2021, combines Spanish …See details»
Agomab Therapeutics to Acquire Origo Biopharma - Business Wire
Oct 28, 2021 Contacts. For Agomab Therapeutics Tim Knotnerus, CEO E-Mail: tim.knotnerus@agomab.com Media Requests for Agomab Dr. Stephanie May or Dr. Laura …See details»
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Dec 15, 2021 Contacts. For Agomab Therapeutics Tim Knotnerus, CEO E-Mail: tim.knotnerus@agomab.com Media Requests for Agomab Dr. Stephanie May or Dr. Laura …See details»
Agomab Spain | Socios Bioga
Agomab Spain (previously Origo Biopharma) is a biotechnology company founded by entrepreneurs with extensive experience in pharmaceutical discovery and development. …See details»
Origo Biopharma S.L. - Life-Sciences-Europe.com
Oct 31, 2021 The first target indication is fibrostenotic Crohn’s disease. A second program, ORG-447, is a lung-restricted ALK-5-inhibitor, currently in IND-enabling studies, for treatment …See details»
Origo Biopharma - PitchBook
Origo Biopharma General Information Description. Developer of organ-restricted drugs intended to address unmet medical needs related to cancer and fibrosis. The company's drug …See details»
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics Completes Acquisition of Origo Biopharma . Ghent, Belgium, December 15, 2021 – Agomab Therapeutics NV (‘Agomab’) announced today theSee details»
Cluster Transfronterizo Biotecnológico
Www.origobiopharma.com; Origo Biopharma Description. We are a pharmaceutical company focused on the research and development of new immunotherapeutic products with the …See details»
Cluster Transfronterizo Biotecnológico
Www.origobiopharma.com; Origo Biopharma Descripción. Somos una empresa farmacéutica enfocada en la investigación y desarrollo de nuevos productos inmunoterapéuticos con el …See details»
Origo Biopharma - Overview, News & Similar companies - ZoomInfo
View Origo Biopharma (www.origobiopharma.com) location in Galicia, Spain , revenue, industry and description. Find related and similar companies as well as employees by title and much …See details»
Origo Biopharma - VentureRadar
Similar Companies: Sun BioPharma USA Privately Held Sun BioPharma is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators, and …See details»
Agomab Acquires Origo Biopharma, Will Develop Fibrosis Therapies
Oct 29, 2021 “We view this acquisition as a unique opportunity to accelerate the further development of our programs as part of a highly competent and committed organization. We …See details»
Agomab Therapeutics to Acquire Origo Biopharma | AseBio
Jan 19, 2022 The combined organization will focus on translating growth factor signaling pathways into innovative therapies. Agomab’s hepatocyte growth factor (HGF)-targeting …See details»
Origo Biopharma raises 2,3M€ in Series Seed financing
Origo Biopharma announced today the closing of a €2,3 million Series Seed financing, with the participation from Sabadell Asabys, XesGalicia and the founding shareholders.The financing, …See details»
Origo Biopharma S.L. | Insights
Nov 5, 2021 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»